Fatal hepatic decompensation in a patient with hepatitis B cirrhosis following famciclovir withdrawal

Robert P Myers MD1, Rabindra Chaudhary PhD2, Kevin Fonseca PhD3, Samuel S Lee MD1

Hepatitis B virus (HBV) infection is a major cause of chronic liver disease worldwide. Famciclovir is a nucleoside analogue with potent antiviral activity that appears promising in the management of patients with HBV infection. No data exist regarding the safety of nucleoside analogue withdrawal in patients treated for HBV cirrhosis. The authors describe a 41-year-old man with compensated HBV cirrhosis who developed fatal hepatic decompensation due to a rebound in viral replication within six weeks of discontinuing famciclovir therapy. Although several mutations in the HBV DNA polymerase gene have been documented, none has been associated with famciclovir resistance or adverse clinical outcomes. Clinicians should consider the risk of inducing serious flares in hepatic inflammation as a result of abrupt nucleoside analogue withdrawal. Until further data are available regarding the safety of withdrawal of these agents, indefinite treatment may be required in patients with established cirrhosis.

Key Words: Adverse effects; Amino acid sequence; 2-Aminopurine analogues and derivatives; Antiviral agents; DNA-directed DNA polymerase; Famciclovir; Hepatitis B virus; Lamivudine; Mutation

Décompensation hépatique fatale chez un patient atteint de cirrhose liée à l'hépatite B après l'arrêt du famciclovir

RÉSUMÉ : Le virus de l'hépatite B (HBV) est une importante cause de maladie hépatique chronique dans le monde. Le famciclovir est un analogue nucléosidique qui exerce une puissante activité antivirale et semble promettre pour le traitement des patients infectés par le HBV. On ne dispose d'aucune donnée sur l'innocuité des analogues nucléosidiques lorsqu'ils sont cessés chez des patients traités pour une cirrhose liée au HBV. Les auteurs décrivent ici le cas d'un homme de 41 ans souffrant d'une cirrhose liée au HBV compensée qui a développé une décompensation hépatique fatale due à une réplication virale de rebond dans les six semaines qui ont suivi l'arrêt de son traitement au famciclovir. Bien que plusieurs mutations du gène de la polymérase de l'ADN du HBV aient été documentées, aucune n'a été associée à la résistance au famciclovir ou à une évolution clinique défavorable. Les médecins doivent tenir compte du risque d'induire de graves poussées d'exacerbation de l'inflammation hépatique par suite de l'arrêt brusque du traitement aux analogues nucléosidiques. Tant qu'on ne disposera pas de données plus abondantes au sujet des conséquences de l'arrêt de ces agents, il faudra peut-être administrer un traitement ininterrompu aux patients souffrant d'une cirrhose avérée.
The patient was then monitored for three years without receiving therapy for HBV infection. He remained positive for HBsAg during the majority of this interval, but the patient was asymptomatic (Child-Pugh class A). In October 1997, the ALT concentration was 341 U/L, and the HBV DNA concentration was 86 pg/mL (Abbott hybridization assay). The patient was then started on famciclovir 500 mg tid in mid-November. Three weeks after starting therapy, the patient’s HBV DNA concentration had decreased to 9.4 pg/mL, but he remained HBsAg positive. The ALT concentration also decreased to 191 U/L. Six months later, the famciclovir was discontinued because of persistent HBsAg positivity. The patient remained asymptomatic, and the examination was unchanged.

Five weeks after stopping treatment, the patient was re-assessed. Shortly after discontinuing famciclovir, he noticed increasing jaundice, fatigue, and testicular swelling. On examination, the patient was jaundiced and had a right hydrocele. The remainder of the examination was unchanged. Laboratory investigations revealed an ALT concentration of 208 U/L, a bilirubin concentration of 38 µmol/L, an international normalized ratio (INR) of 2.6 and an albumin concentration of 30 g/L. He remained HBsAg positive and anti-HBc negative. The HBV DNA concentration had increased dramatically to 533 pg/mL. Because there was evidence of hepatic decompensation thought to be secondary to increased viral replication, the patient was started on lamivudine 150 mg/day.

Five days later, the patient was hospitalized with increasing jaundice, ascites, and diffuse abdominal discomfort. He had no fever or history of gastrointestinal hemorrhage. Physical examination revealed marked jaundice, tense ascites, edema, splenomegaly and asterixis. The ALT and bilirubin concentrations had risen to 710 U/L and 402 µmol/L, respectively. The albumin concentration was 22 g/L, glucose concentration 2.6 mmol/L and INR 3.6. He was positive for HBsAg but negative for HBV DNA. The patient was treated with diuretics and lactulose, as well as ceftriaxone empirically for spontaneous bacterial peritonitis. Famciclovir 500 mg tid was reintroduced. The patient was discharged two weeks later after gradual symptomatic improvement. On discharge, the ALT concentration had fallen to 190 U/L, but the bilirubin concentration had risen to 565 µmol/L.

Six days later, the patient was re-admitted for management of an upper gastrointestinal hemorrhage and hepatic encephalopathy. Urgent gastroscopy and band ligation were performed for bleeding esophageal varices. Laboratory investigations revealed an ALT concentration of 182 U/L, a bilirubin concentration of 550 µmol/L, an albumin concentration of 18 g/L and an INR of 2.8. The patient was not considered a candidate for liver transplantation because his most recent available HBV DNA test was positive, which is a contraindication to liver transplantation. The patient died 12 days later as a result of progressive hepatic and renal failure complicated by pulmonary edema refractory to medical management.

The HBV DNA polymerase gene from a blood sample...
collected six days before the patient’s death was sequenced using standard methods (8). Several mutations in the amino acid sequence of the polymerase were found (Figure 1).

DISCUSSION

The nucleoside analogues lamivudine and famciclovir are promising alternatives to interferon in the management of patients with chronic HBV infection (3,4). Although thousands of patients have been treated with these agents, the safety of their withdrawal in patients with compensated cirrhosis has yet to be reported. As illustrated by this case, discontinuation of nucleoside analogue therapy in patients with significant HBV-related liver disease can result in serious flares of hepatic inflammation.

In this case, we believe that there was a causal relationship between the withdrawal of famciclovir therapy and the patient’s fatal decompensation. Perhaps most striking is the temporal relationship between famciclovir discontinuation and the patient’s clinical deterioration; within six weeks of stopping famciclovir, the patient presented with severe hepatitis. Although known to have cirrhosis on liver biopsy five years previously, the patient had no prior evidence of decompensation. The dramatic increase in HBV DNA concentration (9.4 to 533 pg/mL) lends further support to the hypothesis that famciclovir withdrawal led to a rebound in viral replication and ultimately the patient’s demise.

An alternative but less likely explanation for the patient’s deterioration is that a famciclovir-resistant mutant developed, permitting uncontrolled viral replication. Numerous studies have documented the emergence of drug-resistant HBV strains during monotherapy with nucleoside analogues (9,10). During 12 months of lamivudine treatment, approximately 14% of patients develop mutations in the YMDD motif of the viral polymerase (4). In an analogous fashion, several mutations in the polymerase have been identified in patients displaying breakthrough viremia during famciclovir therapy (11,12). In our patient, several mutations were identified, but none has been implicated in the development of famciclovir resistance or adverse clinical events.

Some authors have expressed concern that the emergence of drug-resistant mutants in patients treated with nucleoside analogues may preclude individuals from liver transplantation (13). This is an important consideration, particularly in Canada, where negative serum HBV DNA is a prerequisite for transplantation. As illustrated by this case, the withdrawal of drug therapy due to fear of these mutants may have disastrous clinical consequences for a patient with established cirrhosis.

The patient described in this case developed fatal hepatic decompensation due to a rebound in viral replication shortly after the discontinuation of famciclovir therapy. Although additional data regarding the safety of nucleoside analogue withdrawal in patients with compensated HBV cirrhosis are required to confirm our findings, we suggest that indefinite treatment may be required in patients with borderline hepatic reserve.

REFERENCES


Can J Gastroenterol Vol 14 No 8 September 2000 727